Gilead Sciences (GILD) Accounts Payables (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Accounts Payables data on file, last reported at $645.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 12.48% year-over-year to $645.0 million; the trailing twelve-month figure through Mar 2026 stood at $645.0 million (down 12.48% YoY), and the FY2025 full-year result was $715.0 million, down 14.17% from the prior year.
• Accounts Payables for Q1 2026 stood at $645.0 million, down from $715.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $905.0 million in Q4 2022 and bottomed at $537.0 million in Q2 2024.
• The 5-year median for Accounts Payables is $622.0 million (2023), against an average of $672.6 million.
• The widest annual swing landed in 2023, when Accounts Payables sank 39.23%; it then jumped 54.1% in 2024.
• A 5-year view of Accounts Payables shows it stood at $905.0 million in 2022, then tumbled by 39.23% to $550.0 million in 2023, then soared by 51.45% to $833.0 million in 2024, then slipped by 14.17% to $715.0 million in 2025, then retreated by 9.79% to $645.0 million in 2026.
• The last three Accounts Payables figures came in at $645.0 million (Q1 2026), $715.0 million (Q4 2025), and $808.0 million (Q3 2025), per Business Quant data.

Peer Comparison